Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

HungaryBack to Hungary

Clinical trials in Zalaegerszeg – page 8

118 clinical trials in Zalaegerszeg, Hungary across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Zalaegerszeg at a glance
118
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

118 trials in Zalaegerszeg

Open in trial search

Triple negative breast cancer

Not recruiting

Study on the Effectiveness and Safety of Datopotamab Deruxtecan Compared to Chemotherapy in Adults with Advanced Triple-negative Breast Cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Elacestrant and Standard Endocrine Therapy for Patients with Early Breast Cancer at High Risk of Recurrence

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Stemline Therapeutics Inc.

Hypertrophic cardiomyopathy

Not recruiting

Study on Sotagliflozin for Improving Symptoms in Patients with Hypertrophic Cardiomyopathy

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Sotagliflozin
  • Sponsor:Lexicon Pharmaceuticals Inc.

Breast cancer+1

Not recruiting

Study of PF-07220060 and Fulvestrant for Adults with Advanced or Metastatic HR-positive, HER2-negative Breast Cancer After Previous Treatment

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Pfizer Inc.

Study on the Effects of FDY-5301 for Patients with Anterior ST-Elevation Myocardial Infarction (Heart Attack)

Not recruiting
Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Iodide
  • Sponsor:Faraday Pharmaceuticals Inc.

Neovascular age-related macular degeneration

Not recruiting

Study of OPT-302 and Aflibercept for Patients with Wet Age-related Macular Degeneration

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Opthea Limited

Breast cancer

Not recruiting

Study of Camizestrant and CDK4/6 Inhibitor for Patients with Advanced Breast Cancer with ESR1 Mutation

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

Hypertriglyceridaemia

Not recruiting

Study on Plozasiran and ARO-APOC3 for Adults with Severe Hypertriglyceridemia

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Cardiac failure acute

Not recruiting

Study of dapagliflozin effects in patients hospitalized with acute heart failure

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin Propanediol Monohydrate
  • Sponsor:The Brigham And Women’s Hospital Inc.

Malignant peritoneal neoplasm+2

Not recruiting

Study Comparing Paclitaxel, Carboplatin, and Oregovomab with Paclitaxel, Carboplatin, and Placebo for Patients with Advanced Ovarian Cancer

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Oregovomab
  • Sponsor:Canariabio Inc.

Small cell lung cancer

Not recruiting

Study on Pembrolizumab, Etoposide, and Cisplatin or Carboplatin for First-Line Treatment in Patients with Extensive-Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Boserolimab
  • Sponsor:Merck Sharp & Dohme LLC

Squamous cell carcinoma of head and neck

Not recruiting

Study of TransCon TLR7/8 Agonist, TransCon IL-2 β/γ, and Pembrolizumab for Patients with Advanced Head and Neck Cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years
  • Substances:ACP-017
  • Sponsor:Ascendis Pharma Oncology Division A/S

Other cities in Hungary

The busiest research cities in the country

All 71 cities in Hungary

Clinical research in Zalaegerszeg

What the registry says about research in the country

01 Cardiovascular Research

Innovative clinical trials focusing on atherosclerotic cardiovascular disease and heart conditions. Studies evaluate new treatments for heart failure, stroke prevention, and post-heart attack recovery.

  • Heart Failure Management
  • Stroke Prevention
  • Cardiovascular Risk Reduction

Current trials are investigating medications for hypertrophic cardiomyopathy and post-stroke treatment options.

02 Oncology Studies

Comprehensive research into breast cancer treatments, particularly focusing on hormone receptor-positive and triple-negative variants. Studies evaluate novel therapeutic approaches.

  • Breast Cancer Therapies
  • Metastatic Disease Treatment
  • Targeted Drug Development

Multiple trials are exploring new treatment options for various stages of breast cancer.

03 Metabolic Disorders

Research initiatives examining treatments for Type 2 Diabetes and obesity. Studies focus on cardiovascular outcomes and weight management solutions.

  • Diabetes Management
  • Weight Control
  • Metabolic Health

Current studies evaluate innovative medications for improved metabolic control.

Back to HungaryAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.